Program
remlifanserin
Its studies are mostly in Hallucinations · Lewy Body Disease, led by ACADIA Pharmaceuticals.
Furthest: phase 3, since Nov 27, 20234 company-led studies, 4 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ACADIA Pharmaceuticals | 44 open or running | phase 3since Nov 27, 2023 | Nov 27, 2023 | Jan 2028phase 3 · NCT06159673 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2023First study: phase 3 study in HallucinationsFirst studyNCT06159673 · 1,074 planned · United States, Brazil, Bulgaria and more
- Dec 22, 2023Phase 3 study in HallucinationsNCT06194799 · 752 planned · United States, Brazil, Bulgaria and more
- Jun 12, 2025Phase 2 study in Lewy Body Dementia PsychosisNCT07029581 · 180 planned · United States, Bulgaria, Czechia and more
- Jul 24, 2025Phase 3 study in Lewy Body Dementia PsychosisNCT07095465 · 126 planned · United States, Bulgaria, Czechia and more
Ahead
- Jan 2028Primary completion: phase 3 study in HallucinationsNCT06159673
- Feb 2028Primary completion: phase 2 study in Lewy Body Dementia PsychosisNCT07029581
- Feb 2029Primary completion: phase 3 study in Lewy Body Dementia PsychosisNCT07095465
- Apr 2029Primary completion: phase 3 study in HallucinationsNCT06194799
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07095465Lewy Body Dementia Psychosis · United States, Bulgaria, Czechia and more | 3 | Recruiting | Feb 2029 | 126 |
| NCT07029581Lewy Body Dementia Psychosis · United States, Bulgaria, Czechia and more | 2 | Recruiting | Feb 2028 | 180 |
| NCT06194799Hallucinations · United States, Brazil, Bulgaria and more | 3 | By invitation | Apr 2029 | 752 |
| NCT06159673Hallucinations · United States, Brazil, Bulgaria and more | 3 | Recruiting | Jan 2028 | 1,074 |
How it is read
Names in the registry
- “ACP-204”, 4 entries
Conditions, from the studies’ own filings
- Hallucinations, 2 studies
- Lewy Body Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.